<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607226</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003698</org_study_id>
    <secondary_id>26236</secondary_id>
    <nct_id>NCT04607226</nct_id>
  </id_info>
  <brief_title>Effects of Respiratory-Gated Transcutaneous Vagal Nerve Stimulation in Major Depression (Phase 1)</brief_title>
  <official_title>A Translational Approach to Cardiorespiratory-Gated Stimulation of the Auricular Branch of the Vagus Nerve for the Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the short term effects of respiratory-gated transcutaneous vagus&#xD;
      nerve stimulation on the regulation of cardiovagal activity, depressive symptomatology and&#xD;
      immune function in subjects with major depression and determine the optimal stimulation&#xD;
      frequency for this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the acute effects of respiratory-gated transcutaneous vagus nerve&#xD;
      stimulation (tVNS) at different stimulation frequencies and sham stimulation during five&#xD;
      sessions within a 2 week period. Heart rate variability (HRV) point process adaptive&#xD;
      filtering estimation algorithms will be used to evaluate changes in cardiac autonomic&#xD;
      physiology in subjects with major depression in response to tVNS. The effects of tVNS on&#xD;
      cardiovagal regulation will be evaluated at rest and in response to an emotion reactivity&#xD;
      task. Depression rating scales (Beck's Depression Inventory) will be used to evaluate short&#xD;
      term effects of tVNS on depressive symptoms in these subjects. In addition, the study will&#xD;
      evaluate the acute effects of the stimulation on serum levels of pro-inflammatory cytokines.&#xD;
      The stimulation frequency that produces the greatest regulatory effects on depressive&#xD;
      symptoms and physiological variables in this population will be used in a second longitudinal&#xD;
      phase of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac autonomic function</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes in cardiac autonomic function (High Frequency power-Heart Rate Variability) between active and sham tVNS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms assessed by the Beck Depression Inventory</measure>
    <time_frame>1 hour</time_frame>
    <description>Changes from baseline to post-stimulation in the score of the Beck Depression Inventory will be compared between active and sham tVNS. (Beck depression inventory minimum score= 0, maximum score= 63; higher total scores indicate more severe depressive symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of pro-inflammatory cytokines</measure>
    <time_frame>2 hours</time_frame>
    <description>Changes in serum levels of proinflammatory cytokines (Interleukin 1B, Interleukin 6, Tumor necrosis factor alfa) from baseline to post-stimulation will be assessed and compared between active and sham tVNS</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Active tVNS - 2 Hz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active tVNS - 8 Hz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active tVNS - 30 Hz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active tVNS - 100 Hz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tVNS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham transcutaneous vagus nerve stimulation on the left auricle</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active transcutaneous vagus nerve stimulation</intervention_name>
    <description>respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes</description>
    <arm_group_label>Active tVNS - 100 Hz</arm_group_label>
    <arm_group_label>Active tVNS - 2 Hz</arm_group_label>
    <arm_group_label>Active tVNS - 30 Hz</arm_group_label>
    <arm_group_label>Active tVNS - 8 Hz</arm_group_label>
    <other_name>Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS)</other_name>
    <other_name>transcutaneous vagus nerve stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham transcutaneous vagus nerve stimulation</intervention_name>
    <description>stimulation of the auricle for 30 minutes</description>
    <arm_group_label>Sham tVNS</arm_group_label>
    <other_name>transcutaneous vagus nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of recurrent Major Depressive Disorder with a current active depressive&#xD;
             episode&#xD;
&#xD;
          -  Currently not taking psychiatric medications or on a stable therapeutic dose of&#xD;
             psychiatric medication for at least 30 days prior to entering the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardio-, cerebro-, or peripheral vascular disease, diabetes mellitus,&#xD;
             morbid obesity (BMI &gt; 40 kg/m2), kidney or liver failure, history of unexplained&#xD;
             fainting spells&#xD;
&#xD;
          -  Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar&#xD;
             disorders, severe personality disorders)&#xD;
&#xD;
          -  Any chronic condition affecting movement, speech and/or ability to read or follow&#xD;
             written instructions&#xD;
&#xD;
          -  Substance use disorder, either mild, moderate, or severe within the past 12 months&#xD;
             (excludes nicotine)&#xD;
&#xD;
          -  History of suicide attempt within the last year or current active suicidal ideation&#xD;
&#xD;
          -  History of a clinically defined neurological disorder including, but not limited to:&#xD;
             Any condition likely to be associated with increased intracranial pressure; space&#xD;
             occupying brain lesion; History of cerebrovascular accident; Transient ischemic attack&#xD;
             within two years; Cerebral aneurysm; Dementia; Parkinson's Disease; Huntington's&#xD;
             chorea; or Multiple sclerosis.&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Metallic implants or devices contraindicating tVNS&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald G Garcia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronald G Garcia, MD, PhD</last_name>
    <phone>617-643-4265</phone>
    <email>rgarciagomez@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Colleen Sheller, BS</last_name>
    <phone>617-726-9725</phone>
    <email>csheller@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald G Garcia, MD, PhD</last_name>
      <phone>617-643-4265</phone>
      <email>rgarciagomez@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ronald Gerardo Garcia Gomez,M.D.,Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Transcutaneous Vagus Nerve Stimulation</keyword>
  <keyword>Cardiac autonomic function</keyword>
  <keyword>Depressive symptomatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

